From the publisher feed

Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:

Read the original at STAT ↗

Opens the original publisher page. Access, copyright and subscriptions are controlled by the publisher.

A useful next step

  1. Read the short publisher description here.
  2. Open the full report directly at the publisher.
  3. Compare this topic with other sources when useful.